FDA lists eight withdrawn immune globulin lots over hypersensitivity reactions

What happened

FDA's Center for Biologics Evaluation and Research (CBER) has published its calendar-year 2026 list of voluntary lot withdrawals for intravenous immune globulin (IGIV) and subcutaneous immune globulin (IGSC). The list covers eight lots of four products: Alyglo, Gammaked, Gamunex-C and Yimmugo.

According to CBER, the manufacturers withdrew the lots after a higher rate of allergic reactions. Some of these reactions were considered medically significant. The withdrawals are described as voluntary, meaning the companies initiated them rather than FDA ordering them.

The record does not say how the eight lots divide between the four products. It also gives no lot numbers, reaction counts, withdrawal dates or root cause, and it does not say whether any supply shortage has followed. Teams should treat those points as not yet known and check the CBER page directly for lot-level detail.

Why it matters

Immune globulin products are biologics derived from human plasma. Hypersensitivity reactions are a recognised class of adverse event for them, so a reaction itself is not unusual. What makes this notable is the stated trigger: a higher rate of allergic reactions, with some judged medically significant. That implies a signal at lot level, not isolated individual case reports.

Four different products are on the list. The record does not say whether the withdrawals share a cause, and it would be speculative to suggest so. Both IGIV and IGSC routes are covered, so the issue is not tied to one route of administration, at least on the information available.

Regulatory context

Voluntary lot withdrawals are a standard tool in biologics oversight. A manufacturer that sees a quality or safety concern in a specific lot can remove it from distribution, and FDA publishes the information so that healthcare providers, distributors and patients can act. For plasma-derived products, lot-specific action is typically the first line of response because the concern may relate to a particular manufacturing run, not the whole product.

Pharmacovigilance sits behind such decisions. Adverse event reports, complaint trending and lot-level analysis can show a pattern that prompts action. A withdrawal does not by itself establish a causal link or a manufacturing defect. The records do not say what investigation is under way or whether any labelling change is being considered.

The wider news flow shows how different regulators handle product-level problems. On 28 October, Health Canada posted a recall notice for Siemens Healthineers imaging software that truncates the final cardiac phase in a calculation, which is a device defect with a defined technical cause. The immune globulin record has no comparable explanation yet, which is why lot-level transparency and follow-up communication will matter.

Who is affected

Marketing authorisation holders for immune globulin products should check whether their own pharmacovigilance and complaint data show any hypersensitivity trend. They should also confirm that lot-release and distribution records can support a fast, lot-specific response. Quality teams should confirm that recall and market-withdrawal procedures can trace distribution down to the lot.

Distributors, specialty pharmacies and infusion providers handling any of the four named brands should check inventory against the CBER list. Clinicians and pharmacists will need to know how to handle affected product already dispensed, but the record gives no instructions on that point.

Supply continuity is a separate concern. The records do not report a shortage. Still, in the EU, companies should note an unrelated national change: from 1 November 2026, an amendment to Slovak Act No. 362/2011 Coll. alters how marketing authorisation holders notify interruptions and cessations of supply of human medicines. The source gives no detail on the new requirements, and nothing links the amendment to immune globulins. It is a reminder that withdrawals can trigger supply-interruption duties that vary by country, and that notification procedures should be current.

What to watch

The key unknowns are the cause of the reactions, the number and severity of reports, and whether further lots or products are added to the list. CBER's page is a running calendar-year list, so more entries are possible, though the record does not say so.

Also watch for any FDA communication on the cause, for manufacturer notices to healthcare providers, and for signs of supply effects on patients who depend on immune globulin therapy. None of these is reported in the current record.